CG104

Principal Investigator:
John Collins, MD               (MCVI)
Gregory Pellizzon, MD       (Midland)
Stephen Mattichak, MD      (Bay City)

Sub-Investigators:
Peter Fattal, MD
Rao Gudipati, MD
Safwan Kassas, MD
William Felten, MD
Daniel Lee, MD

Sponsor:
Cogentus Pharmaceuticals, Inc.

Study Purpose:
A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease

Objective:
To compare the rates of stomach ulcers and stomach bleeding that occurs when taking either CGT-2168 (the new combination drug) and aspirin or Plavix® (a drug to prevent blood clots) and aspirin. Aspirin also helps prevent blood clots, and is often used with Plavix®. The study doctors will also monitor both the safety of the new drug, and whether it works effectively as a combination treatment for blood-clotting and digestive tract disorders.

Status:
Active enrollment

If you have any questions, please feel free to contact the coordinators, and they will be happy to answer any questions you have regarding this study.

<< Back